Related Experiment Video
Updated: Apr 4, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy
Sjoerd A M E G Timmermans1, Myrurgia A Abdul Hamid, Jan Willem Cohen Tervaert
1Departments of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
Background:
The natural course of idiopathic membranous nephropathy (MN) varies, as it is known through favorable outcomes in most patients. However, one third of patients with idiopathic MN will slowly progress to end-stage renal disease (ESRD). To prevent disease progression, patients at high risk to develop ESRD are treated with immunosuppressive agents. Therefore, a correct selection of patients who need immunosuppressive treatment is important.
Methods:
Here, we evaluated the prognostic value of anti-phospholipase A2 receptor 1 antibody (anti-PLA2R) levels regarding clinical outcome in a well-defined cohort of 73 PLA2R-related MN patients with long-term follow-up. At baseline, patients were subdivided into patients with either low or high antibody levels based on ELISA testing.
Results:
Spontaneous remission rates were highest among patients with low anti-PLA2R levels (79%; hazard ratio 2.72 (95% CI 1.22-6.08), p = 0.02) after a median follow-up of 2.9 (95% CI 0.8-5.0, p < 0.001) years, whereas high anti-PLA2R levels were associated with persistent proteinuria (p = 0.04) and/or the need for immunosuppressive therapy (p < 0.001). Renal survival rates were 97% at 5 years, 93% at 10 years, and 89% at 15 years; however, this was not different between the anti-PLA2R groups. ESRD occurred significantly faster in patients with severe proteinuria as compared to patients with either mild (p = 0.02) or moderate proteinuria (p = 0.05).
Conclusions:
Low anti-PLA2R levels may predict spontaneous remissions in patients with PLA2R-related MN. Therefore, we suggest that quantification of anti-PLA2R is of value to monitor these patients.
Insights
Low anti-phospholipase A2 receptor 1 antibody (anti-PLA2R) levels predict spontaneous remission in idiopathic membranous nephropathy (MN). Monitoring anti-PLA2R levels can help identify patients who may not require immunosuppressive therapy.
Area of Science:
- Nephrology
- Immunology
- Clinical Medicine
Background:
- Idiopathic membranous nephropathy (MN) has variable outcomes, with one-third progressing to end-stage renal disease (ESRD).
- Immunosuppressive therapy is used for high-risk MN patients to prevent ESRD, necessitating accurate patient selection.
- Anti-phospholipase A2 receptor 1 antibody (anti-PLA2R) is a key marker in PLA2R-related MN.
Purpose of the Study:
- To evaluate the prognostic value of anti-PLA2R antibody levels in predicting clinical outcomes in PLA2R-related MN.
- To determine if anti-PLA2R levels can guide treatment decisions and patient monitoring.
- To assess the correlation between anti-PLA2R levels and disease remission or progression.
Main Methods:
- A cohort of 73 patients with PLA2R-related MN was studied with long-term follow-up.
- Anti-PLA2R antibody levels were measured at baseline using ELISA and categorized as low or high.
- Clinical outcomes, including spontaneous remission, proteinuria, need for immunosuppression, and renal survival, were analyzed.
Main Results:
- Spontaneous remission was significantly higher in patients with low anti-PLA2R levels (79%; HR 2.72, p=0.02).
- High anti-PLA2R levels correlated with persistent proteinuria (p=0.04) and the need for immunosuppressive therapy (p<0.001).
- While overall renal survival was high (89% at 15 years), ESRD progression was faster in patients with severe proteinuria.
Conclusions:
- Low anti-PLA2R antibody levels are a valuable predictor of spontaneous remission in PLA2R-related MN.
- Quantification of anti-PLA2R antibodies is recommended for monitoring patients with MN.
- This marker can aid in identifying patients who may benefit from conservative management instead of immunosuppression.
More Related Videos
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022